Low-dose growth hormone-releasing factor may enhance folliculogenesis in regularly menstruating women: a preliminary study

• Published in: Fertility and sterility Vol. 63; no. 4; pp. 756 - 760
• Main Authors: Duffy, Daniel M., Lindheim, Steven R., Vijod, Marcela A., Chang, Lilly, Nakamura, Robert M., Lobo, Rogerio A.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.1995; Elsevier Science
• Subjects: Adult; Biological and medical sciences; Endometrium - diagnostic imaging; Endometrium - drug effects; Endometrium - growth & development; Estradiol - blood; Female; folliculogenesis; FSH; Fundamental and applied biological sciences. Psychology; Growth hormone-releasing factor; Growth Hormone-Releasing Hormone - administration & dosage; Growth Hormone-Releasing Hormone - pharmacology; Hormone metabolism and regulation; Hormones - blood; Humans; Mammalian female genital system; Menstrual Cycle - physiology; Ovarian Follicle - diagnostic imaging; Ovarian Follicle - drug effects; Ovarian Follicle - growth & development; Prospective Studies; Ultrasonography; Vertebrates: reproduction; folliculogenesis; FSH; Growth hormone-releasing factor; E2; Human; Low dose; Estrogen; 17β-Estradiol; Gonadotropin; Ovarian hormone; Hypothalamic hormone; Ovary; Adenohypophyseal hormone; Female genital system; Hormonal regulation; Development; Female; Hormone releasing factor; Ovarian follicle; STH-RH
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/S0015-0282(16)57477-9

To evaluate the effect of low-dose GH-releasing factor (GRF) on folliculogenesis in regularly menstruating women. Prospective clinical trial where individual patients served as their own control. Outpatient Reproductive Endocrine/Infertility Clinic of the Los Angeles County-University of Southern California Medical Center, Los Angeles, California. Seven regularly menstruating women. During treatment cycles, subjects received 100 μg SC GRF on cycle days 2 to 11 and were observed during a control cycle. Follicle number and diameter, as well as endometrial thickness were all assessed by vaginal ultrasound and blood was obtained for serum FSH, LH, E2, P, GH, insulinlike growth factor 1 (IGF-1), and insulin-like growth factor binding protein-3. During cycles treated with GRF, GH, and IGF-1 levels were normal. However, follicular growth rates and E2 to FSH ratios were significantly higher. The day of the peak E2 to follicular diameter ratio after GRF was earlier than in control cycles. Endometrial growth rates were also greater with GRF. Our data, although preliminary, support the hypothesis that low doses of GRF may independently stimulate the ovary and enhance folliculogenesis.